LXRX vs. CLDX, INVA, DVAX, MNKD, OPK, NVAX, GERN, RGLS, MYGN, and ZBIO
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.
Lexicon Pharmaceuticals vs. Its Competitors
Celldex Therapeutics (NASDAQ:CLDX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.
Lexicon Pharmaceuticals has a net margin of -568.04% compared to Celldex Therapeutics' net margin of -2,366.07%. Celldex Therapeutics' return on equity of -23.46% beat Lexicon Pharmaceuticals' return on equity.
Celldex Therapeutics currently has a consensus price target of $50.11, suggesting a potential upside of 134.93%. Lexicon Pharmaceuticals has a consensus price target of $3.67, suggesting a potential upside of 300.03%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.
74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 4.4% of Celldex Therapeutics shares are held by insiders. Comparatively, 13.9% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Celldex Therapeutics. MarketBeat recorded 2 mentions for Lexicon Pharmaceuticals and 1 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.16 beat Lexicon Pharmaceuticals' score of 0.89 indicating that Celldex Therapeutics is being referred to more favorably in the media.
Celldex Therapeutics has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Celldex Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Summary
Celldex Therapeutics and Lexicon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LXRX) was last updated on 7/8/2025 by MarketBeat.com Staff
